Your Local Stores Delivered - Shipt Same-Day Delivery
National favorites. Delight in every delivery. Order groceries, everyday essentials, and so much more from your favorite stores — delivered the same day by friendly shoppers who care about getting things just right. Above and beyond.
Secondary hyperparathyroidism: symptoms, causes & treatment
2024年6月6日 · What is secondary hyperparathyroidism (SHPT)? Secondary hyperparathyroidism (SHPT) is a type of hyperparathyroidism. SHPT happens when a disease you have causes low blood calcium, which makes your parathyroid glands grow larger and make too much parathyroid hormone (PTH). What causes SHPT?
Secondary Hyperparathyroidism - StatPearls - NCBI Bookshelf
2023年8月28日 · Secondary hyperparathyroidism (SHPT) is an increased secretion of PTH due to parathyroid hyperplasia caused by triggers such as hypocalcemia, hyperphosphatemia, or decreased active vitamin D. The increased PTH secretion, in turn, causes increased calcium in the blood by acting on bones, intestines, and kidneys.
Secondary hyperparathyroidism - Wikipedia
Secondary hyperparathyroidism is the medical condition of excessive secretion of parathyroid hormone (PTH) by the parathyroid glands in response to hypocalcemia (low blood calcium levels), with resultant hyperplasia of these glands. This disorder …
Secondary hyperparathyroidism - BMJ Best Practice
2024年4月4日 · Secondary hyperparathyroidism (SHPT) is elevation of parathyroid hormone (PTH) secondary to hypocalcemia. PTH maintains calcium homeostasis by acting on the renal tubules, on calcium stores in the skeletal system, and indirectly on the gastrointestinal tract through activation of vitamin D and en...
Advances in the treatment of secondary and tertiary ...
2022年12月22日 · Secondary hyperparathyroidism (SHPT) and tertiary hyperparathyroidism (THPT) are common and complicated clinical endocrine diseases. The parathyroid glands maintain endocrine homeostasis by secreting parathyroid hormone to …
Treatment of Hyperparathyroidism (SHPT) - PMC
With the progression of SHPT, there is a histological modification of the parathyroid glands. Diffuse hyperplasia becomes nodular, with decreased expression of vitamin D receptors (VDR) and Ca-sensing receptor (CaR), which may result in resistance to pharmacological treatment.